| RNA velocity of single cells G La Manno, R Soldatov, A Zeisel, E Braun, H Hochgerner, V Petukhov, ... Nature 560 (7719), 494-498, 2018 | 3251 | 2018 |
| Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines I Litvan, JG Goldman, AI Tröster, BA Schmand, D Weintraub, RC Petersen, ... Movement disorders 27 (3), 349-356, 2012 | 2800 | 2012 |
| A functional role for adult hippocampal neurogenesis in spatial pattern separation CD Clelland, M Choi, C Romberg, GD Clemenson Jr, A Fragniere, ... Science 325 (5937), 210-213, 2009 | 1965 | 2009 |
| Evolution of cognitive dysfunction in an incident Parkinson's disease cohort CH Williams-Gray, T Foltynie, CEG Brayne, TW Robbins, RA Barker Brain 130 (7), 1787-1798, 2007 | 1196 | 2007 |
| The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort CH Williams-Gray, JR Evans, A Goris, T Foltynie, M Ban, TW Robbins, ... Brain 132 (11), 2958-2969, 2009 | 1174 | 2009 |
| Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands R Cools, RA Barker, BJ Sahakian, TW Robbins Cerebral cortex 11 (12), 1136-1143, 2001 | 1136 | 2001 |
| Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease AA Kehagia, RA Barker, TW Robbins The Lancet Neurology 9 (12), 1200-1213, 2010 | 1130 | 2010 |
| Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis D Aarsland, K Bronnick, C Williams-Gray, D Weintraub, K Marder, ... Neurology 75 (12), 1062-1069, 2010 | 1086 | 2010 |
| The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study T Foltynie, CEG Brayne, TW Robbins, RA Barker Brain 127 (3), 550-560, 2004 | 956 | 2004 |
| Molecular diversity of midbrain development in mouse, human, and stem cells G La Manno, D Gyllborg, S Codeluppi, K Nishimura, C Salto, A Zeisel, ... Cell 167 (2), 566-580. e19, 2016 | 816 | 2016 |
| The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort CH Williams-Gray, SL Mason, JR Evans, T Foltynie, C Brayne, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (11), 1258-1264, 2013 | 738 | 2013 |
| Targeting huntingtin expression in patients with Huntington’s disease SJ Tabrizi, BR Leavitt, GB Landwehrmeyer, EJ Wild, C Saft, RA Barker, ... New England Journal of Medicine 380 (24), 2307-2316, 2019 | 698 | 2019 |
| Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry SJG Lewis, A Dove, TW Robbins, RA Barker, AM Owen Journal of Neuroscience 23 (15), 6351-6356, 2003 | 698 | 2003 |
| Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach SJG Lewis, T Foltynie, AD Blackwell, TW Robbins, AM Owen, RA Barker Journal of Neurology, Neurosurgery & Psychiatry 76 (3), 343-348, 2005 | 695 | 2005 |
| L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease R Cools, RA Barker, BJ Sahakian, TW Robbins Neuropsychologia 41 (11), 1431-1441, 2003 | 671 | 2003 |
| Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis AA Kehagia, RA Barker, TW Robbins Neurodegenerative diseases 11 (2), 79-92, 2012 | 600 | 2012 |
| The spectrum of nonmotor symptoms in early Parkinson disease TK Khoo, AJ Yarnall, GW Duncan, S Coleman, JT O’Brien, DJ Brooks, ... Neurology 80 (3), 276-281, 2013 | 576 | 2013 |
| A cell atlas of human thymic development defines T cell repertoire formation JE Park, RA Botting, C Domínguez Conde, DM Popescu, M Lavaert, ... Science 367 (6480), eaay3224, 2020 | 564 | 2020 |
| Microglial activation correlates with severity in Huntington disease: a clinical and PET study N Pavese, A Gerhard, YF Tai, AK Ho, F Turkheimer, RA Barker, DJ Brooks, ... Neurology 66 (11), 1638-1643, 2006 | 542 | 2006 |
| Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial S Palfi, JM Gurruchaga, GS Ralph, H Lepetit, S Lavisse, PC Buttery, ... The Lancet 383 (9923), 1138-1146, 2014 | 534 | 2014 |
